ABMD News and Press, ABIOMED Inc. From 11/05/20

Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the Impella 5.5 with SmartAssist heart pump in the first year after the U.S. Food and Drug Administration (FDA) granted Impella 5.5 with SmartAssist its highest level of approval for safety and efficacy. ...

Image source: The Motley Fool. Abiomed Inc (NASDAQ: ABMD) Q2 2021 Earnings Call Oct 29, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Abiomed Inc (ABMD) Q2 2021 Earnings Call Transcript

Shares of Abiomed (NASDAQ: ABMD) closed down 10% today after the medical-device maker reported earnings from its second fiscal quarter and muted guidance for the quarter ahead due to the COVID-19 pandemic. Revenue was up 27% from the first quarter as hospitals opened up and doct...

Abiomed, Inc. (ABMD) Q2 2021 Earnings Conference Call October 29, 2020 08:00 ET Company Participants Mike Minogue - Chairman, President and Chief Executive Officer Todd Trapp - Vice President and Chief Financial Officer Conference Call Participants Margaret Kaczor - William Blair Matthew O'Br...

ALACHUA, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended September 30, 2020. ...

Abiomed ([[ABMD]] -8.1%) FQ2 earnings results as follows:Revenue: $209.8M (+27% Q/Q) (+2% Y/Y)Worldwide Impella® heart pump revenue: $199.7M (+29% Y/Y).Operating income: $61.3M (+2% Y/Y)Gross margin: 81.5% vs. 83.0% last year.Operating cash flow: $77.2MFQ3 revenue outlook: $221M-230...

Abiomed (ABMD): Q2 Non-GAAP EPS of $1.01 beats by $0.04; GAAP EPS of $1.36 beats by $0.56.Revenue of $209.76M (+2.3% Y/Y) beats by $6.87M.Press Release For further details see: Abiomed EPS beats by $0.04, beats on revenue

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported second quarter fiscal 2021 revenue of $209.8 million, a sequential increase of 27% compared to Q1 fiscal year 2021 and a year over year increase of 2% compared to Q2 fiscal year 20...

Abiomed (NASDAQ:ABMD) is scheduled to announce Q2 earnings results on Wednesday, October 28th, after market close.The consensus EPS Estimate is $0.97 (-5.8% Y/Y) and the consensus Revenue Estimate is $202.89M (-1.0% Y/Y).Estimated Expenses on a non-GAAP basis R&D $27.6M and SG&A ...

Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart pump in the world. It measures 9 French (Fr) (3 millimeters) in diameter upon insertion and removal from the body. Whi...